IP-10 has been observed to inhibit the growth of malignancies such as cervical cancer through anti-angiogenic and anti-viral mechanisms [25], while it has been observed to promote growth of malignancies such as breast cancer through the CXCR3-A receptor variant [24]. Here, CXCL10 is linked to breast carcinoma.